facebook_pixel
Equity Strategy 31 July 2013
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
DBS Drops $6.5 Billion Danamon Bid After Failing to Win Control. Take Profit

DBS Drops $6.5 Billion Danamon Bid After Failing to Win Control. Take Profit

* DBS Group Holdings Ltd. ended a bid to acquire PT Bank Danamon Indonesia for $6.5 billion in what would have been Southeast Asia’s largest banking takeover after failing to win regulatory approval for a majority stake. * The agreement with Danamon’s biggest shareholder, Temasek Holdings Pte, will lapse after tomorrow’s deadline, Singapore- based DBS […]

FIND OUT MORE

Blog Video 31 July 2013
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Infinity Pharmaceuticals: Clearing The Confusion

Infinity Pharmaceuticals: Clearing The Confusion

* Infinity Pharmaceuticals, Inc. researches and develops cancer drugs.  The Company uses small  molecule drug technologies in the development of its products * Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty […]

FIND OUT MORE

FX Strategy 30 July 2013
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
USD/MYR: Buy. Fitch Revises Malaysia’s Outlook to Negative

USD/MYR: Buy. Fitch Revises Malaysia’s Outlook to Negative

* Fitch Revises Malaysia’s Outlook to Negative; Affirms Ratings * SocGen: Fitch’s Outlook Revision Negative for Ringgit; 1-mo. ringgit forwards will fall to 3.35/dlr after Fitch Ratings cut Malaysia’s outlook to negative from stable, Societe Generale strategist Wee-Khoon Chong says in research note • The revision “would only fuel further negative sentiment in Malaysia and […]

FIND OUT MORE